Literature DB >> 10383140

CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1.

V Nedelcheva Kristensen1, E K Haraldsen, K B Anderson, P E Lønning, B Erikstein, R Kåresen, O S Gabrielsen, A L Børresen-Dale.   

Abstract

The ability of a motif of the CYP17 5' untranslated region, created by a polymorphic T to C substitution, to bind to the human transcription factor Sp-1 was investigated. No binding of any of the polymorphic alleles was observed in electromobility shift assay. No other sequence within +1 to +100 of each of the CYP17 alleles formed complex with the Sp-1 or enhanced binding to the polymorphic CACC box. Genotyping of 510 breast cancer patients and 201 controls revealed no difference in genotype frequencies. Age at onset, tumor grade, lymph node status and distant metastases, stage, and estrogen and progesterone receptor status were not associated with the CYP17 genotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383140

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  CYP17 polymorphisms and prostate cancer outcomes.

Authors:  Jonathan L Wright; Erika M Kwon; Daniel W Lin; Suzanne Kolb; Joseph S Koopmeiners; Ziding Feng; Elaine A Ostrander; Janet L Stanford
Journal:  Prostate       Date:  2010-07-01       Impact factor: 4.104

3.  CYP17 polymorphism (rs743572) is associated with increased risk of gallbladder cancer in tobacco users.

Authors:  Rajani Rai; Kiran L Sharma; Sanjeev Misra; Ashok Kumar; Balraj Mittal
Journal:  Tumour Biol       Date:  2014-04-01

4.  Genetic polymorphisms of ESR1, ESR2, CYP17A1, and CYP19A1 and the risk of breast cancer: a case control study from North India.

Authors:  Shilpi Chattopadhyay; Sarah Siddiqui; Md Salman Akhtar; Mohammad Zeeshan Najm; S V S Deo; N K Shukla; Syed Akhtar Husain
Journal:  Tumour Biol       Date:  2014-01-16

5.  Basal levels of DNA damage detected by micronuclei and comet assays in untreated breast cancer patients and healthy women.

Authors:  Raquel A Santos; Ana Cláudia Teixeira; Monica B Mayorano; Hélio H A Carrara; Jurandyr M Andrade; Catarina S Takahashi
Journal:  Clin Exp Med       Date:  2009-11-10       Impact factor: 3.984

6.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

7.  Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.

Authors:  Daphne W Bell; Brian W Brannigan; Keitaro Matsuo; Dianne M Finkelstein; Raffaella Sordella; Jeff Settleman; Tetsuya Mitsudomi; Daniel A Haber
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

8.  Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes.

Authors:  C Torresan; M M C Oliveira; G T Torrezan; S F V de Oliveira; C S Abuázar; R Losi-Guembarovski; R S Lima; C A Urban; I J Cavalli; E M S F Ribeiro
Journal:  Clin Exp Med       Date:  2008-07-11       Impact factor: 3.984

9.  Genetic variation in CYP17 and endometrial cancer risk.

Authors:  Mia M Gaudet; James V Lacey; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; Stephen Chanock; Montserrat Garcia-Closas
Journal:  Hum Genet       Date:  2008-01-03       Impact factor: 4.132

10.  Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.

Authors:  Lori C Sakoda; Christie Blackston; Jennifer A Doherty; Roberta M Ray; Ming Gang Lin; Helge Stalsberg; Dao Li Gao; Ziding Feng; David B Thomas; Chu Chen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-05       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.